DOCS - Top-Line Growth Visibility Deteriorates as Investment Weighs on Margin Outlook; Follow-up Call Takeaways

Research evidence excerpt

DOCS - Top-Line Growth Visibility Deteriorates as Investment Weighs on Margin Outlook; Follow-up Call Takeaways

Truist Securities

Equity Research Report May 14, 2026

HEALTHCARE: HCIT Doximity, Inc. (DOCS)

DOCS - Top-Line Growth Visibility Deteriorates as Investment Jailendra Singh

212-401-4406 Weighs on Margin Outlook; Follow-up Call Takeaways

Jailendra.Singh@truist.com

Payton Engdahl We provide key takeaways from our post earnings follow-up call with Doximity. For reference,

212-319-5476 DOCS posted FY4Q26 results which fell relatively in line with expectations (see our DOCS

Payton.Engdahl@truist.com - Quick Take - FY4Q26 Print in 60 Seconds). DOCS also provided its 1Q and FY2027

guidance that came in below investor expectations on both revenue and adjusted EBITDA.

Eduardo Ron Our PT is now $19 (vs $29 previously). Reiterate Hold.

212-326-3152

Eduardo.Ron@truist.com

Bottom Line. In mid-April, we downgraded DOCS from Buy to Hold due to concerns

that revenue growth visibility was softening and structural risks were mounting. Our

KOL checks have consistently pointed to limited clarity around pharma digital marketing

Stock Rating HOLD budgets, alongside emerging competitive pressure from AI-native platforms. Heading into

Unchanged the print, we expected DOCS to guide below consensus; however, the FY27 outlook

came in below even our own expectations on both revenue and EBITDA. DOCS has

Price Target $19.00 now transitioned from a clear growth leader to a more mature, challenged platform with

↓ rising risk of incremental share erosion. We have seen with multiple HCIT companies in

from the past that when revenue growth visibility diminishes and competitive pressure intensifies,

$29.00 valuations can remain depressed for a prolonged period. Our updated FY27 and FY28